VanEck ETF Trust - VanEck Biotech ETF Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on VanEck ETF Trust - VanEck Biotech ETF's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Capital Markets Industry Growth | 10.3% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Earnings Update | n/a |
Recent past performance updates
No updates
Recent updates
BBH ETF: Buy This ETF At Discounted Price And Hold It For Long Term
Apr 28XBI And IBB: Sell Technology And Buy Biotech, The Only Undervalued Non-Cyclical Growth Sector
Feb 15BBH: Better Than IBB For Covid Exposure Including The Omicron Variant
Nov 30BBH: This ETF Provides Robust Returns To Investors In The Biotech Sector
Sep 26In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, VanEck ETF Trust - VanEck Biotech ETF has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How VanEck ETF Trust - VanEck Biotech ETF makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|
Quality Earnings: Insufficient data to determine if BBH has high quality earnings.
Growing Profit Margin: Insufficient data to determine if BBH's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if BBH's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare BBH's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: Insufficient data to determine if BBH's earnings growth over the past year exceeded the Capital Markets industry average.
Return on Equity
High ROE: BBH has a negative Return on Equity (0%), as it is currently unprofitable.